About Flare Therapeutics
Flare Therapeutics is a clinical-stage biotechnology company exclusively focused on drugging transcription factors (TFs) to develop small molecule precision medicines for oncology and other diseases. The company's proprietary discovery engine leverages proteomics, mass spectrometry, and a library of electrophilic compounds to identify 'switch sites' — novel druggable pockets within transcription factor complexes. Its lead pipeline programs target advanced urothelial cancer (FX-909, a PPARG inhibitor in Phase I) and prostate cancer (FX-111 ARON degrader), with a partnership with Roche.
Company details
Funding
Total raised
$205M
Last stage
Series B
Investors
Founders
Steven McKnight
Scientific co-founder and Chair of the Scientific Advisory Board at Flare Therapeutics; pioneering biochemist whose research on transcription factors forms the foundation of the company.
Robert Sims
Industry leader in drug discovery of gene control. Former entrepreneur-in-residence at Third Rock Ventures and founding scientist/SVP of Research at Constellation Pharmaceuticals. Ph.D. in Cellular and Molecular Biology from the University of Texas at Austin.
LinkedInFraydoon Rastinejad
Scientific co-founder inspired by seminal work on the HIF2A transcription factor at Oxford University. Elucidated the structural basis for bidirectional tuning of gene regulation by HIF2A using small molecules.
Mitchell Lazar
Scientific co-founder of Flare Therapeutics, with expertise in transcription factor biology.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.